2026-09-21 · KeXinMaterials 編集チーム

GxP 良好実施ファミリー + EU GMP 付録 1 + 付録 11 + 付録 15 資格 無菌 コンピュータ化 保護ケース B2B ガイド

GxP (Good x Practice) ファミリーは GLP (実験室)、GCP (臨床)、GMP (製造)、GDP (分質)、GVP (薬品警戒)を含めます。EU GMP 付録 1 (無菌製造)、付録 11 (コンピュータ化システム)、付録 15 (資格 + 検証) は B2B 薬品機器スープライヤーの三つの最も重要な付録です。以下に 2026 B2B 採購ガイドを示します: 範囲、無菌クリーンルーム設計、コンピュータ化システム検証 (CSV)、資格プロトコル期待。

GxP ファミリー概要

GxP is the umbrella term for Good x Practice standards covering different phases of pharmaceutical product lifecycle. Each GxP addresses specific regulatory + operational requirements.

GxP family: GLP (Good Laboratory Practice) + GCP (Good Clinical Practice) + GMP (Good Manufacturing Practice) + GDP (Good Distribution Practice) + GVP (Good Pharmacovigilance Practice) + GPP (Good Pharmacy Practice).

GLP (Good Laboratory Practice): 21 CFR Part 58 (FDA) + OECD GLP Principles (EU). Applies to non-clinical laboratory studies that support or are intended to support applications for research or marketing permits for products. Includes study director, study plan, SOPs, equipment, raw data, archived samples, QA unit.

GCP (Good Clinical Practice): ICH E6(R2) + 21 CFR Part 312 + EU Directive 2001/20/EC. Applies to clinical trials. Includes IRB/IEC, informed consent, investigator brochure, study protocol, monitoring, audit, electronic data capture (EDC).

GMP (Good Manufacturing Practice): 21 CFR 211 (US) + EU GMP Guidelines (EudraLex Vol 4) + Japan PMDA GMP. Applies to drug product manufacturing. Already covered in R2 A2.

GDP (Good Distribution Practice): EU GDP 2013/C 343/01 (covered in R2 A1) + WHO TRS 957. Applies to wholesale distribution of medicinal products.

GVP (Good Pharmacovigilance Practice): EU GVP Guidelines (Modules I-XVI) + ICH E2D. Applies to adverse drug reaction (ADR) reporting, periodic safety update reports (PSURs), risk management plans (RMPs), signal detection, benefit-risk assessment.

GPP (Good Pharmacy Practice): WHO Joint Standards FIP/WHO. Applies to community + hospital pharmacy practice. Includes dispensing, patient counseling, medication management.

B2B relevance: For B2B pharmaceutical equipment + protective case suppliers, GxP compliance depends on where equipment is used. GLP for lab equipment. GMP for manufacturing equipment (most common). GDP for transport equipment. GCP for clinical trial supply.

Quality agreement: Cross-GxP coverage in quality agreement between equipment manufacturer + pharmaceutical client. Defines responsibilities per applicable GxP regime.

B2B recommendation: For 2026 pharma B2B orders, identify applicable GxP regime + EU GMP Annex 1/11/15 compliance + 21 CFR 211 + 21 CFR Part 11 + ICH Q10 support + audit access.

EU GMP 付録 1 無菌製造

EU GMP Annex 1 (Sterile Manufacturing, August 2023 update) specifies GMP requirements for sterile medicinal products. Critical for inner protective case used in sterile manufacturing or aseptic processing.

EU GMP Annex 1 scope: Sterile medicinal products manufactured by aseptic processing OR terminal sterilization. Includes small molecules + biologics + cell therapies + gene therapies + vaccines + ATMPs.

Annex 1 Section 3 (Cleanroom Design): Grade A (ISO 5, LAF cabinet + RABS + isolator), Grade B (ISO 5 background for Grade A), Grade C (ISO 7), Grade D (ISO 8). Air flow, pressure differential (10-15 Pa between adjacent grades), HEPA filtration, air changes per hour (20-600/hr).

Annex 1 Section 4 (Cleanroom Qualification): Initial qualification (IQ/OQ/PQ) + re-qualification (annual + after change). Particle count (ISO 14644-1), microbial monitoring (settle plates + active air sampling + contact plates + glove print), temperature + humidity mapping.

Annex 1 Section 5 (Personnel): GMP-trained gowning procedure, microbiological monitoring of operators (gloves + gown), training records, behavior in cleanroom (slow movements, no talking over product).

Annex 1 Section 7 (Equipment): Equipment designed for aseptic operation (smooth surfaces, no crevices, cleanable, sterilizable). CIP/SIP or COP/SOP capability. Single-use preferred where feasible.

Annex 1 Section 8 (Sanitation): Cleaning agent compatibility, validated cleaning procedure, environmental monitoring after cleaning, sanitizer efficacy testing.

Annex 1 Section 9 (Production): Aseptic process simulation (APS, also "media fill") required annually per process + filling line + shift. Successful APS = 0 contaminated units in 5000-10000 filled units.

Annex 1 Section 10 (Filtration): Sterilizing filter (0.2 micron) for aseptic filtration. Filter integrity test (bubble point + diffusion) before + after filtration. Pre-use + post-use.

Annex 1 Section 11 (Sterilization): Terminal sterilization preferred over aseptic processing. Moist heat (121°C 15 min minimum, F0 calculation), dry heat (160°C 2 hr), EtO, gamma, VHP. SAL 10⁻¶.

Annex 1 Section 12 (Single-Use Systems SUS): Pre-validated disposable equipment (bags, tubing, filters, connectors). Extractables + leachables per USP <88> + USP <665>. Vendor qualification + change control.

Annex 1 Section 13 (Quality Risk Management): QRM per ICH Q9 throughout process design + qualification + monitoring + change control + continuous improvement.

B2B relevance: For B2B pharmaceutical equipment suppliers, EU GMP Annex 1 compliance is mandatory for all sterile product contact equipment. Critical for inner protective case used in aseptic processing.

B2B recommendation: For 2026 EU-bound pharma B2B orders, supply protective case with: ISO 5 cleanroom compatibility, smooth surfaces (Ra <0.8 micron), validated cleaning + sterilization procedure, USP <88> Class VI materials, validated SAL 10⁻¶ sterilization, full environmental monitoring data, change control procedure, Q9 risk assessment documentation.

EU GMP 付録 11 コンピュータ化システム

EU GMP Annex 11 (Computerised Systems) specifies requirements for GMP-regulated computer systems. All software + hardware used in pharmaceutical manufacturing + distribution must comply.

EU GMP Annex 11 scope: All GMP-regulated computer systems. Includes LIMS, ERP, MES, LIMS, QMS, document management, training records, complaint handling, recall, batch records, lab data, control systems, monitoring systems.

Annex 11 Section 1 (Risk Management): Computer system risk assessment per ICH Q9. Identify GMP impact + patient impact + data integrity impact. Risk-based validation scope.

Annex 11 Section 3 (Suppliers): Supplier assessment, quality agreement, audits, change notification, security updates, patch management.

Annex 11 Section 4 (Validation): Computer system validation per GAMP 5 categories. Category 1 (infrastructure software), Category 3 (configurable COTS), Category 4 (configured COTS), Category 5 (custom). Validation per URS, FS, DS, IQ, OQ, PQ.

Annex 11 Section 5 (Data): Data criticality + risk assessment. Data integrity (ALCOA+ principles: Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, Available).

Annex 11 Section 6 (Accuracy): Data accuracy + precision verified. Calculations + algorithms tested. Critical calculations double-checked or cross-verified.

Annex 11 Section 7 (Data Storage): Data stored for life of product + 1 year minimum (typically 10-30 years). Backup + archive + retrieval tested. Disaster recovery tested.

Annex 11 Section 8 (Printouts): Printouts must reproduce original data accurately. Must be readable + reproducible. Audit trail printed on demand.

Annex 11 Section 9 (Audit Trails): Audit trail for all GMP-critical data changes. Includes who, when, before, after, why. Audit trail enabled by default, immutable, retained per data retention.

Annex 11 Section 10 (Change Control): Change control for any system change (configuration, code, data structure). Impact assessment + validation + approval.

Annex 11 Section 11 (Periodic Review): Periodic review of computer systems. Typically annually. Verify continued fitness for purpose + change control + incident management.

Annex 11 Section 12 (Security): Access controls (unique user IDs, password policies, MFA). Role-based access. Segregation of duties. Account management + provisioning + deprovisioning.

Annex 11 Section 13 (Electronic Signatures): Per 21 CFR Part 11 + EU Annex 11. Biometric or unique credential + password. Signature manifestation (printed name + date/time + meaning). Signature/record link.

Annex 11 Section 14 (Batch Release): Electronic batch release per 21 CFR Part 11. QP verification + electronic signature + audit trail.

Annex 11 Section 15 (Business Continuity): Disaster recovery + business continuity plan. Critical systems backed up + tested.

B2B relevance: For B2B pharmaceutical equipment suppliers, Annex 11 applies if equipment has computer components (PLC, HMI, SCADA, sensors). Critical for monitoring systems + control systems + audit trail.

B2B recommendation: For 2026 EU-bound pharma B2B orders, supply equipment with: computer system validation scope per GAMP 5, ALCOA+ data integrity, audit trail enabled, role-based access, electronic signature per 21 CFR Part 11, periodic review scope, change control procedure.

EU GMP 付録 15 資格 + 検証

EU GMP Annex 15 (Qualification + Validation, 2015 revision) specifies requirements for qualification of equipment, utilities, premises + validation of processes + cleaning + analytical methods.

Annex 15 scope: Qualification of equipment + utilities + premises. Validation of processes + cleaning + analytical methods. Computer system validation per Annex 11 + GAMP 5.

Annex 15 Section 2 (Glossary): Defines terms: installation qualification (IQ), operational qualification (OQ), performance qualification (PQ), validation, qualification, verification, worst case, critical process parameter (CPP), critical quality attribute (CQA).

Annex 15 Section 3 (Organisation + Planning): Validation Master Plan (VMP), project plan, responsibilities, documentation, change control.

Annex 15 Section 4 (Documentation): VMP, qualification protocol + report, validation protocol + report, supporting documentation (URS, FS, risk assessment, etc.). All signed by QA + relevant functions.

Annex 15 Section 5 (Qualification Stages): URS (User Requirements Specification), FS (Functional Specification), DS (Design Specification), IQ (Installation Qualification), OQ (Operational Qualification), PQ (Performance Qualification).

Annex 15 Section 6 (Equipment Qualification): Equipment qualification scope: critical equipment + non-critical equipment. Risk-based qualification. Supplier qualification may substitute parts of IQ + OQ.

Annex 15 Section 7 (Utilities Qualification): Water systems (PW + WFI), steam systems, compressed air, HVAC. Validation per applicable pharmacopeia + ISPE baseline guide.

Annex 15 Section 8 (Premises Qualification): Cleanroom qualification per ISO 14644 + EU GMP Annex 1. Particle + microbial monitoring. Re-qualification annual + after change.

Annex 15 Section 9 (Process Validation): Stage 1 Process Design (per FDA 2011 Process Validation + ICH Q8 + Q11). Stage 2 Process Qualification (IQ/OQ/PQ). Stage 3 Continued Process Verification (CPV vs APR/PQR).

Annex 15 Section 10 (Cleaning Validation): Cleaning validation per FDA + ICH + EU Annex 15. Acceptance criteria (TOC + HPLC + visual + microbial + endotoxin). Worst case product + equipment. Hold time studies.

Annex 15 Section 11 (Analytical Method Validation): Analytical method validation per ICH Q2(R1). Specificity, accuracy, precision, linearity, range, LOD, LOQ, robustness.

Annex 15 Section 12 (Computer System Validation): Per Annex 11 + GAMP 5. Risk-based validation scope.

Annex 15 Section 13 (Verification of Transportation): Per EU GDP Annex 1 + WHO TRS 961. Transport route validation. Temperature mapping. Stability budget verification.

Annex 15 Section 14 (Revalidation): Periodic review + revalidation when change control identifies significant change.

B2B relevance: For B2B pharmaceutical equipment suppliers, Annex 15 covers equipment qualification + process validation + cleaning validation + transport verification.

B2B recommendation: For 2026 EU-bound pharma B2B orders, supply equipment with: URS template, IQ/OQ protocol templates, validation support scope, cleaning validation data, transport verification report, periodic review scope, revalidation criteria.

クロス GxP コンプライアンス戦略

B2B pharmaceutical equipment suppliers typically serve multiple GxP regimes (GLP + GCP + GMP + GDP). Cross-GxP compliance strategy needed to avoid duplicate validation + documentation.

Common GxP requirements: Documentation, QMS (ISO 9001 or equivalent), change control, training records, audit trail, supplier qualification, complaint handling, CAPA, deviation management.

Regime-specific requirements: GLP (study director, study plan, raw data retention), GCP (informed consent, IRB/IEC, EDC), GMP (IQ/OQ/PQ, batch records, validation, environmental monitoring), GDP (transport verification, stability budget), GVP (ADR reporting, RMP, PSUR).

Master Validation Plan (VMP): Covers all GxP regimes. Defines validation scope + responsibility + schedule + documentation per regime.

Quality Agreement: Cross-regime quality agreement between equipment manufacturer + client. Defines responsibilities + change control + documentation + audit + complaint + CAPA per regime.

Audit access: Client + regulator audits of equipment manufacturer. Per GxP regime, client may audit manufacturer to verify compliance with applicable requirements.

Supplier qualification: Client qualifies equipment manufacturer per applicable GxP. Site audit + document review + questionnaire + reference checks + sample evaluation.

B2B relevance: For B2B pharmaceutical equipment manufacturers serving multiple GxP regimes, cross-GxP compliance strategy + master documentation + quality agreement template + unified audit framework enables serving multiple clients efficiently.

B2B recommendation: For 2026 multi-regime pharma B2B orders, establish: cross-GxP quality management system, unified documentation templates, master validation plan, cross-regime quality agreement template, unified supplier qualification procedure, shared audit response process, GxP-specific addenda to standard documentation.

保護ケース相関

Protective cases for pharmaceutical applications must comply with applicable GxP regime (GMP most common) AND relevant EU GMP Annex 1/11/15 if used in sterile manufacturing + computerised systems + qualification + validation scope.

GxP regime: For pharmaceutical manufacturing, GMP regime applies. For distribution, GDP regime. For clinical trial supply, GCP regime. For laboratory studies, GLP regime.

EU GMP Annex 1: For sterile manufacturing, inner case must be ISO 5 cleanroom compatible, smooth surfaces (Ra <0.8 micron), no crevices, validated cleaning + sterilization (SAL 10⁻¶). USP <88> Class VI materials. Validated environmental monitoring.

EU GMP Annex 11: If inner case has computer components (temperature monitor + data logger + RFID reader), comply with Annex 11 requirements: GAMP 5 validation scope, ALCOA+ data integrity, audit trail, role-based access, electronic signature per 21 CFR Part 11, periodic review.

EU GMP Annex 15: For equipment qualification + transport verification. Supplier provides IQ/OQ/PQ protocol templates + cleaning validation data + transport verification report + revalidation criteria.

Cross-GxP: For multi-regime applications, supplier should have cross-GxP quality management system + unified documentation + master validation plan + cross-regime quality agreement.

Quality agreement scope: Responsibilities + change control + documentation + audit + complaint + CAPA per regime. Defined between supplier + client.

Validation support scope: Validation support engineer ($5-15k/engineer) + IQ/OQ/PQ protocol templates + SAT + FAT + calibration + training records + spare parts list + change control procedure + revalidation criteria.

Quality system certification: ISO 9001 + (for sterile) ISO 13485 (medical device) + audit access + supplier qualification + quality agreement template.

Documentation: Material certificates (USP Class VI), surface finish certificates (Ra), dimensional inspection, welding documentation (per ASME BPE for bio-pharma), FAT/SAT reports, IQ/OQ support, cleaning validation data, sterilization validation data, environmental monitoring data, change control records.

B2B relevance: For B2B pharmaceutical equipment + protective case suppliers, GxP + EU GMP Annex 1/11/15 compliance is mandatory for serving pharmaceutical clients globally.

B2B recommendation: For 2026 pharma B2B orders, supply protective case with: applicable GxP compliance statement, EU GMP Annex 1/11/15 compliance statement, USP Class VI materials, ISO 5 cleanroom compatibility, validated cleaning + sterilization procedure, IQ/OQ/PQ protocol templates, computer system validation scope if applicable, validation support engineer, cross-GxP quality agreement, full material traceability, change control procedure, periodic review scope.

よくある質問

関連記事

• 21 CFR 211 cGMP + ICH Q10 + 薬品検証ファミリー
• EU GDP 2013/C 343/01 + WHO TRS 961 + ICH Q1A ファーマシーストクレスチェーン
• ISO 13485 医療機器 QMS